Signablok, Inc.
Publicly observedWorcester, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Worcester | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Signablok, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | JM5UN38YM1H7 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant4 Sept 2026Publicly observed
NIH SBIR/STTR award: New TREM-1 therapy for inflammatory bowel disease
USD 353,264.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant15 Sept 2025Publicly observed
NIH SBIR/STTR award: TREM-1 therapy for the treatment of empyema
USD 457,954.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
- Grant30 Sept 2023Publicly observed
NIH SBIR/STTR award: First-in-class TREM-1 inhibitors for neovascular retinal diseases
USD 830,491.00 · National Eye Institute · Source: NIH RePORTER (opens in a new tab)
- Grant30 Sept 2023Publicly observed
NIH SBIR/STTR award: First-in-class TREM-1 inhibitors for neovascular retinal diseases
USD 830,491.00 · National Eye Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.